Curing the Incurable – This Gene Therapy Delivers

The first approved gene therapy for a neuromuscular disease s now  available for children with spinal muscular atrophy (SMA) thanks to AveXis, a Novartis company.

SMA is caused by a mutated or missing survival motor neuron 1 gene (SMN1) that prevents the body from making enough survival motor neuron protein (SMN), ultimately leading to the loss of motor neurons, muscle weakness, and paralysis seen in SMA.

Newborn screening requirements for SMA in Arizona is the next important step.

Continue reading

Startup to Commercialize Blood Test for Most Major Cancers

When testing for such as lung cancer disease, doctors know that tissue biopsies are necessary and potentially life-saving, though the procedures used to gather tissue can lead to dangerous complications, from bleeding to lung collapse. To lower the need for invasive procedures, researchers at the University of Arizona developed a new blood test that can detect most major cancers and have launched a startup, DesertDx, to bring the invention to doctors and their patients.Continue reading

Northern Arizona University Recognizes Retired CEO of Blue Cross Blue Shield of Arizona With Honorary Doctorate Degree

Recognized for his commitment and contributions he has made to healthcare and the community through his leadership, Rich Boals, retired President and CEO of Blue Cross and Blue Shield of Arizona, was conferred an honorary Doctorate of Humane Letters degree by Northern Arizona University (NAU) at the college’s spring 2019 commencement ceremony on Friday, May 10, 2019, in the university’s J. Lawrence Walkup Skydome.Continue reading

Paradigm Diagnostics Announces the Addition of Industry Executive Mara Aspinall to the Board of Directors as Part of the Series B Extension Closing Totaling $15 Million

Paradigm Diagnostics, a leading precision medicine company focused on comprehensive cancer testing, announced the addition of Mara Aspinall, Managing Director of BlueStone Venture Partners to the Board of Directors as part of the closing of Paradigm’s $15 million Series B fundraising.Continue reading

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases. This volume takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease, which is expected to affect more than 13.8 million people in the United States by 2050 and cost well over $1 trillion annually.Continue reading